Dr. Ghazi Alotaibi, Consultant Haematologist, King Saud Medical city and Assistant Professor of Medicine at King Saud University, Riyadh, Saudi Arabia, talks about translating data into practice.

• Discussion about case report with the clinical history and treatment approach 
 with maintenance therapy.

• About the DFCI and WUSTL trails.

• Ongoing ECHO phase III trial.

• Summary of different studies of Ibrutinib, acalabrutinib, Ibrutinib-Rituximab, 
 Dual BTK-BCL2blockade, Zanubrutinib, Venetoclax, Lenalidomide- Rituximab, 
 Brexucabtagene autoleucel from studies conducted by other researchers

 

 

Explore more videos

Configure Image Component

Acalabrutinib and Other Novel Therapies in Mantle Cell Lymphoma

Dr. Michael Wang, US

Configure Image Component

MCL Management in Clinic

Dr. Salem Alshemmari, Kuwait

Configure Image Component

Critical Evaluation of BTKis in CLL

Dr. George Follows, UK

Modal Window Component Section Begins
Modal Window Component Section Ends